Warning Letters | FDA
FDA issued new warning letters targeting dietary supplement companies for labeling violations, including unauthorized structure/function claims, lack of NDI notifications, and GMP non-compliance. This signals increased enforcement scrutiny.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may issue warning letters or seize products at any time.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA published new warning letters highlighting specific labeling violations (e.g., unauthorized claims, missing Supplement Facts, adulteration). This indicates a shift toward stricter enforcement and potential for more inspections.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review all product labels for compliance with FDA labeling requirements, ensure structure/function claims are substantiated and include disclaimers, verify NDI notifications for new ingredients, and audit GMP practices.
Deadline
Immediately; FDA may issue warning letters or seize products at any time.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial